This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, R.
Right arrow Articles by Steckelberg, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, R.
Right arrow Articles by Steckelberg, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2001, p. 621-623, Vol. 45, No. 2
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.2.621-623.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Linezolid Therapy of Vancomycin-Resistant Enterococcus faecium Experimental Endocarditis

Robin Patel,1,2,* Mark S. Rouse,1 Kerryl E. Piper,1 and James M. Steckelberg1

Division of Infectious Diseases and Infectious Diseases Research Laboratory,1 and Division of Clinical Microbiology,2 Mayo Clinic and Foundation, Rochester, Minnesota

Received 6 June 2000/Returned for modification 25 July 2000/Accepted 31 October 2000

We compared the activities of linezolid (25 mg/kg of body weight, administered intraperitoneally every 8 h) and of vancomycin (25 mg/kg of body weight, administered intraperitoneally every 8 h) in a rat model of vanA vancomycin-resistant Enterococcus faecium experimental endocarditis. Results were expressed as median log10 CFU per gram of vegetation after 3 days of treatment. The median log10 CFU per gram of vegetation was 10.1 among 7 untreated control animals, 10.2 among 9 vancomycin-treated animals, and 7.9 among 10 linezolid-treated animals. Linezolid treatment was more active (P < 0.05) than vancomycin treatment or no treatment.

* Corresponding author. Mailing address: Divisions of Clinical Microbiology and Infectious Diseases, Departments of Laboratory Medicine and Pathology and Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905. Phone: (507) 284-3021. Fax: (507) 284-9859. E-mail: patel.robin{at}mayo.edu.

Antimicrobial Agents and Chemotherapy, February 2001, p. 621-623, Vol. 45, No. 2
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.2.621-623.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Fishman, J. A. (2007). Infection in Solid-Organ Transplant Recipients. NEJM 357: 2601-2614 [Full Text]  
  • Athanassopoulos, G., Pefanis, A., Sakka, V., Iliopoulos, D., Perrea, D., Giamarellou, H. (2006). Linezolid in Prophylaxis against Experimental Aortic Valve Endocarditis Due to Streptococcus oralis or Enterococcus faecalis. Antimicrob. Agents Chemother. 50: 654-657 [Abstract] [Full Text]  
  • Singh, K. V., Nallapareddy, S. R., Nannini, E. C., Murray, B. E. (2005). Fsr-Independent Production of Protease(s) May Explain the Lack of Attenuation of an Enterococcus faecalis fsr Mutant Versus a gelE-sprE Mutant in Induction of Endocarditis. Infect. Immun. 73: 4888-4894 [Abstract] [Full Text]  
  • Moellering, R. C. Jr. (2003). Linezolid: The First Oxazolidinone Antimicrobial. ANN INTERN MED 138: 135-142 [Abstract] [Full Text]  
  • Miyazaki, S., Fujikawa, T., Kobayashi, I., Matsumoto, T., Tateda, K., Yamaguchi, K. (2002). The in vitro and in vivo antibacterial characterization of vancomycin and linezolid against vancomycin-susceptible and -resistant enterococci. J Antimicrob Chemother 50: 971-974 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»